Related Experiment Video
Updated: Jul 8, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Sorafenib: in hepatocellular carcinoma
Dene Simpson1, Gillian M Keating
1Wolters Kluwer Health | Adis, Auckland, New Zealand.
Drugs
|January 17, 2008
Summary
Sorafenib, an oral multikinase inhibitor, significantly improves survival for advanced hepatocellular carcinoma patients. Combination therapy with doxorubicin also shows survival benefits, with sorafenib generally well-tolerated.
Area of Science:
- Hepatocellular Carcinoma Research
- Oncology Therapeutics
- Clinical Trial Analysis
Background:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Sorafenib is an approved oral multikinase inhibitor for advanced HCC.
- Effective treatment options for advanced HCC remain critical.
Purpose of the Study:
- To evaluate the efficacy and safety of sorafenib in advanced HCC.
- To assess the potential of combination therapy with sorafenib and doxorubicin in advanced HCC.
- To provide evidence for sorafenib's role in HCC management.
Main Methods:
- Phase III SHARP trial (n=602) assessed sorafenib monotherapy vs. placebo in advanced HCC.
- Phase II study (n=96) evaluated sorafenib plus doxorubicin vs. doxorubicin alone in advanced HCC.
- Both studies were randomized, double-blind, and multicentre.
Main Results:
- Sorafenib significantly improved median survival (10.7 vs. 7.9 months) and time to progression (5.5 vs. 2.8 months) in the SHARP trial.
- Combination therapy demonstrated significantly longer median overall survival and progression-free survival compared to doxorubicin alone.
- Sorafenib monotherapy was generally well-tolerated with a manageable adverse event profile.
Conclusions:
- Sorafenib monotherapy offers significant survival benefits for patients with advanced HCC.
- Combination therapy with sorafenib and doxorubicin presents a promising treatment strategy for advanced HCC.
- Sorafenib exhibits a favorable safety profile in the management of advanced HCC.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...